Brief: Hyloris Pharmaceuticals End-Dec Cash, Cash Equivalents At EUR 50 mln

Hyloris Pharmaceuticals SA

16/03/2022 06:10

March 16 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * STRONG GROWTH IN H2 LEADING TO TOTAL REVENUES OF €3.1
MILLION
(€0.2 MILLION IN 2020)
    * FY OPERATING LOSS EUR 10.5 MLN VS LOSS EUR 7.0 MLN YR AGO
    * FY NET LOSS OF EUR 11.6 MLN VS LOSS EUR 7.1 MLN YR AGO
    * €50 MILLION IN CASH AND CASH EQUIVALENTS TO EXECUTE
AMBITIOUS
GROWTH STRATEGY
    * COVID-19-RELATED RESTRICTIONS AFFECTED SEVERAL OF THE
COMPANY’S
PROGRAMS DURING 2021 WITH MINOR IMPACTS ON TIMELINES
    * HYLORIS HAS 15 PRODUCTS IN DEVELOPMENT6 OF WHICH TWO ARE
COMMERCIALIZED
    * COMPANY IS WELL-CAPITALIZED TO ADVANCE ALL CURRENT
PIPELINE
ASSETS AS PLANNED AND EXECUTE ITS CURRENT BUSINESS PLAN WITH
EXPECTATION TO EXPAND PORTFOLIO TO ABOUT 30 CANDIDATE AND
MARKETED PRODUCTS BY 2024
    * DURING 2022 ANTICIPATES DELIVERING ON KEY VALUE INFLECTION
MILESTONES WITHIN ITS STRATEGIC FOCUS AREAS, INCLUDING
CONDUCTING 6 CLINICAL STUDIES ON ITS PIPELINE PRODUCTS

Source text for Eikon:  ID:nGNE6G56sb 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))